Pfizer Shares Dipped Following Release of Phase III Palbociclib Study Data

Pfizer shared results from its collaborative Phase III Palbociclib Collaborative Adjuvant Study (PALLAS) on Friday, and the data determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival in patients with breast cancer. As a result, shares of the company fell 6% in after-market trading, according to Yahoo! Finance.